22 The administration of reserpine to rodents has been suggested as a 23 pharmacological
model of Parkinson disease (PD) based on the effects 24 of this monoamine-depleting agent …

The systemic administration of low reserpine (RES) doses (0.1–1.0 mg/kg) has been
proposed as a valuable rat model for the study of non-motor symptoms of Parkinson's …

We have recently verified that the monoamine-depleting drug reserpine—at doses that do
not modify motor function—impairs memory in a rodent model of aversive discrimination. In …

Animal models are widely used to study alterations caused by Parkinson's disease (PD).
However, in general, pharmacological models do not express the progressive nature of the …

Contrary to other animal models for Alzheimer's disease (AD) and related cognitive deficits
involving acute memory impairment, the present study was designed to provide an animal …

Rationale Reserpine, a monoamine-depleting agent, which irreversibly and non-selectively
blocks the vesicular monoamine transporter, has been used as an animal model to study …

Studies have suggested that cognitive deficits can precede motor alterations in Parkinson's
disease (PD). However, in general, classic animal models are based on severe motor …

Previous studies have shown that cognitive deficits precede the classical motor symptoms
seen in Parkinson's disease (PD) and that physical exercise may exert beneficial effects on …

The administration of reserpine to rodents was one of the first models used to investigate the
pathophysiology and screening for potential treatments of P arkinson's disease (PD). The …

Parkinson's disease (PD) is mainly characterized by a dopamine deficiency accompanied by
structural and functional changes in striatal neuronal projections. However, studies have …